68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Conditions
Carcinoid Cancer - Neuroendocrine Tumors - Medullary Thyroid Cancer - Cancers Expressing Somatostatin Receptors
Conditions: official terms
Apudoma - Carcinoid Tumor - Neuroendocrine Tumors - Thyroid Neoplasms
Study Type
Expanded Access
Study Phase
N/A
Study Design
N/A
Intervention
Name: 68Ga DOTATATE
Type: Drug
Overall Status
Available
Summary
To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Detailed Description
This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.
Criteria for eligibility
Healthy Volunteers:
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Older than 18 years the time of radiotracer administration

- Provides written informed consent

- Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline

- Able to remain still for duration of each imaging procedure (about 30 minutes)

Exclusion Criteria:

- Less than 18 years-old at the time of radiotracer administration

- Pregnant or nursing

- Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)

- Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
Location
UCLA Hospital
Los Angeles, California, United States
Status:
Contact: Johannes Czernin, MD - jczernin@mednet.ucla.edu
Sponsors
Johannes Czernin
Source
University of California, Los Angeles
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page